Altria Q4 EPS In-Line but Revenue Misses, Where is the Growth?

Tobacco company Altria (NYSE:MO) announced results that exactly met expectations but is still struggling to find growth. Altria wrote off another $4.1 billio... Read More»

Cronos Q4 2018 Earnings Review – The New Most Expensive Stock in Cannabis

In Cronos' (TSX: CRON) latest earnings report, they both grabbed the crown for most expensive cannabis company and disappointed with operations. Impressive.... Read More»

Altria Invests $2.4 Billion in Cronos Group

In an effort to develop new product lines and expand large-scale cultivation capabilities, Cronos Group Inc. (NASDAQ: CRON; TSX: CRON) just closed a significant... Read More»

Cronos – No Cash, No Deal….. Tough Times

Bottom Line The leak of acquisition talks between Cronos and Altria is a classic tactic used by companies to support their share prices prior to raising money.... Read More»

Marijuana Investor Roundup: Analysis of the Week’s Most Important Events (October 13, 2018)

Altria has Aphria in Their Crosshairs Bottom Line: Deal chatter will continue to support the cannabis sector over the next 12 months in our view and any dive... Read More»

Altria has Aphria in their Crosshairs – What a Deal Would Mean for the Cannabis Industry

Altria in Talks with Aphria The Globe and Mail put out an article (Paywall) today saying that Aphria (Ticker: APH.TO) has been holding partnership talks with c... Read More»